Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
|Earning Growth (QoQ)|
|Revenue Growth (QoQ)|
|Held by Institutions %||40%|
|1 Day Vol Adjusted Return||-0.1|
|1 Month Vol Adjusted Return||2.1|
|3 Month Vol Adjusted Return||5.4|
|6 Month Vol Adjusted Return||-4.6|
|20 Days SMA Price ZScore||1.6|
|50 Days SMA Price ZScore||2.2|
|12 -26 Days PPO||5.2|
|1 Month Average Short Volume Ratio||42.8|
|1 Day Volume Change ZScore||-0.1|
|1 Month Daily Vol||9.7|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2) Bioanalytical Systems, Inc. (NASDAQ: BASI) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Cullinan Oncology, Inc. (NASDAQ: CGEM) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Exagen Inc. (NASDAQ: XGN) Fortress Biotech, Inc. (NASDAQ: FBIO) Gemini Therapeutics, Inc. (NASDAQ: GMTX) Glaukos Corp (NYSE: GKOS) iTeos Therapeutics, Inc. (NASDAQ: ITOS) Landos Biopharm...
Michaels, Alcoa, Horizon Acquisition, KemPharm and Ovid Therapeutics are five top gainers for Wednesday.
Takeda Pharmaceutical Co will spend as much as $856 million to secure global rights from Ovid Therapeutics Inc to an experimental drug being developed to treat rare epilepsy, the companies said on Wednesday. Takeda will be responsible for future development and commercialization of the drug, soticlestat, worldwide and Ovid will no longer have any financial obligation, the companies said in a statement. Ovid will receive an upfront payment of $196 million at the close of the agreement, expected...
Takeda has entered into an exclusive agreement with partner Ovid Therapeutics to develop and commercialize the investigational medicine soticlestat.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...